GILD
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Article Summary
HOLD- Gilead Sciences Inc. (Nasdaq: GILD) announced that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes, with management hosting a webcast at 4:30 p.m.
- Eastern Time that day to discuss financial performance and provide a business update.
- The biopharmaceutical company has pursued and achieved breakthroughs in medicine for more than three decades with the goal of creating a healthier world for all people, committed to advancing innovative medicines to prevent and treat life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
- A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year, with Gilead operating in more than 35 countries worldwide.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 3.8% | 25% | 20.0 ptsMinimal (3.8%) - Very weak |
| EPS Growth Next 5Y ? | 9.0% | 25% | 20.0 ptsWeak (9.0%) - Low expectations |
| Target Price Upside ? | 22.6% | 20% | 70.0 ptsGood Upside (22.6%) - Target: $159.74 vs Current: $130.28 |
| Gross Margin % ? | 79.4% | 15% | 100.0 ptsExceptional (79.4%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -17.2% | 15% | 40.0 ptsMild Pullback (-17.2%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About GILD
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
- The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
- It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
- Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
- Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
- The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc.
- It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
- The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.
- The company was incorporated in 1987 and is headquartered in Foster City, California.